Alzheimer’s disease, named after the German psychologist Alois Alzheimer, looks to be an illness of the twentieth century, but the brain degeneration, cognitive impairment and annoying behaviour and psychiatric issues which characterize the illness have most likely been about for centuries.
A quick lesson in Alzheimer’s disease history tells us that while Dr. Alzheimer is the illness’ namesake, Alzheimer’s co-worker Emil Kraepelin played a similarly critical role in the identification of the illness. Kraepelin isolated and grouped together the indications of the disorder, recommending they used to be a unique illness process, while Alzheimer was first to understand what was actually occuring in the brains of Alzheimer’s patients.
He discovered surprising plaques and tangles in the brain of one of his patients, a 50 year old girl, who exhibited the indications of the disorder identified by Kraepelin. After Kraepelin and Alzheimer’s identification of the illness in the early twentieth century, Alzheimer’s disease history shows that hardly any advances were made in understanding or treating the illness, which could only be diagnosed at autopsy with a postmortem, till the end of the twentieth century. The illness was first diagnosed in patients between the ages of forty five and sixty five and labeled as “presenile dementia.” The name Alzheimer’s disease only gained recognition in the 70s and 80s as a label for patients over the age of sixty five.
Now the illness has recognizable and diagnosable symptoms, which can appear in patients as young as thirty. Generally an assertive sort of Alzheimer’s disease that happens in patients younger than the age of sixty five has a known genetic factor, while the appearance of the illness in patients over sixty five has a number of other considerations with regard to its development, like health, occupation, and environment. Current advances in technology and science have led on to a promising new age in Alzheimer’s disease history. Cognex, the 1st FDA-approved drug used to slow the disease process, hit the markets in 1990, and 3 others shortly followed. The medicines slow cognitive impairment in patients with mild to moderate Alzheimer’s disease by increasing burned out levels of acetylcholine in the brain, which are vital to the healthy working of neurons.
Other research is being done on paths to forestall Alzheimer’s from developing.
Certain hormones like estrogen and anti inflammatory drugs like aspirin have been discovered to possess a mediating effect, and environmental components, for example mentally demanding occupations, dance, and chess have been found to decrease older folk’s possibilities of developing Alzheimer’s. Even something as easy as wearing a seatbelt or helmet may be necessary to stopping Alzheimer’s disease. Early detection strategies are being refined to boost treatment of the illness. As an example, genetic research has discovered genetic markers for Familial Alzheimer’s disease as well as non-familial Alzheimer’s. Additionally, advanced technology , for example MRIs and PET scans, are getting used to notice structural changes in the brain that can indicate the development of Alzheimer’s disease before symptoms even begin.
As the Baby Boomer generation starts to age, scientists fear the strain a sizeable number of dementia patients could place on the medical care and social welfare systems; scientists are rushing to make Alzheimer’s disease history.